Company logo

CRBP - Corbus Pharmaceuticals Holdings, Inc.

NASDAQ -> Healthcare -> Biotechnology
Norwood, United States
Type: Equity

CRBP price evolution
CRBP
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Current assets
Cash $14.39 $11.92 $9.02 $7.99
Short term investments $7.18 $17.48 $28.22 $36.9
Net receivables
Inventory
Total current assets $23.55 $31.21 $38.27 $45.86
Long term investments
Property, plant & equipment $4.04 $4.4 $4.76 $5.12
Goodwill & intangible assets
Total noncurrent assets $4.73 $5.08 $5.45 $5.78
Total investments $7.18 $17.48 $28.22 $36.9
Total assets $28.27 $36.28 $43.72 $51.65
Current liabilities
Accounts payable $3.18 $4.71 $1.51 $1.32
Deferred revenue
Short long term debt $17.65 $19.25 $8.42 $6.53
Total current liabilities $31.89 $31.54 $16.39 $14.36
Long term debt $3.24 $3.61 $15.29 $18.31
Total noncurrent liabilities $3.28 $4.43 $17.82 $20.83
Total debt $20.88 $22.86 $23.72 $24.84
Total liabilities $35.18 $35.97 $34.2 $35.19
Shareholders' equity
Retained earnings -$436.68 -$428.66 -$418.61 -$409.83
Other shareholder equity -$0 -$0.01 -$0.02 -$0.07
Total shareholder equity -$6.9 $0.31 $9.52 $16.46
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $14.39 $3.81 $25.68 $86.45
Short term investments $7.18 $42.19 $72.64
Net receivables $0.96
Inventory
Total current assets $23.55 $60.18 $100.2 $92.07
Long term investments
Property, plant & equipment $4.04 $5.5 $7 $9.32
Goodwill & intangible assets
Total noncurrent assets $4.73 $6.13 $7.53 $10.22
Total investments $7.18 $42.19 $72.64
Total assets $28.27 $66.31 $107.73 $102.29
Current liabilities
Accounts payable $3.18 $2.17 $1.78 $7.38
Deferred revenue
Short long term debt $17.65 $4.43 $5 $1.71
Total current liabilities $31.89 $12.64 $17.01 $31.9
Long term debt $3.24 $15.98 $21.59 $25.12
Total noncurrent liabilities $3.28 $20.68 $21.61 $25.12
Total debt $20.88 $25.09 $26.59 $26.84
Total liabilities $35.18 $33.32 $38.62 $57.02
Shareholders' equity
Retained earnings -$436.68 -$392.08 -$349.73 -$304.09
Other shareholder equity -$0 -$0.13 -$0.06 -$0
Total shareholder equity -$6.9 $32.99 $69.11 $45.27
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $6.98 $6.55 $4.25 $13.39
Selling, general & administrative $3.12 $2.94 $3.94 $3.91
Total operating expenses $10.1 $10.05 $8.78 $17.3
Operating income -$10.1 -$10.05 -$8.78 -$17.3
Income from continuing operations
EBIT -$7.31 -$9.29 -$8.01 -$17.07
Income tax expense
Interest expense $0.71 $0.76 $0.78 $0.68
Net income
Net income -$8.02 -$10.05 -$8.78 -$17.74
Income (for common shares) -$8.02 -$10.05 -$8.78 -$17.74
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $0.88 $3.94
Cost of revenue
Gross Profit $0.88 $3.94
Operating activities
Research & development $31.17 $16.14 $36.45 $98.27
Selling, general & administrative $13.91 $18.7 $20.43 $28.48
Total operating expenses $45.08 $39.84 $56.87 $126.75
Operating income -$45.08 -$39.84 -$55.99 -$122.81
Income from continuing operations
EBIT -$41.68 -$40.21 -$43.81 -$110.24
Income tax expense
Interest expense $2.92 $2.13 $1.83 $1.03
Net income
Net income -$44.6 -$42.35 -$45.64 -$111.27
Income (for common shares) -$44.6 -$42.35 -$45.64 -$111.27
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income -$8.02 -$10.05 -$8.78 -$17.74
Operating activities
Depreciation $0.15 $0.15 $0.16 $0.18
Business acquisitions & disposals
Stock-based compensation $0.8 $0.82 $0.82 $1.03
Total cash flows from operations -$6.01 -$7.18 -$7.8 -$15.11
Investing activities
Capital expenditures
Investments $10.39 $10.9 $8.81 $5.55
Total cash flows from investing $10.39 $10.9 $8.81 $5.55
Financing activities
Dividends paid
Sale and purchase of stock $0 $0.01 $0.2 $0.04
Net borrowings -$1.83 -$0.74 -$0.15 -$0.15
Total cash flows from financing -$1.9 -$0.82 $0.02 -$0.11
Effect of exchange rate
Change in cash and equivalents $2.47 $2.9 $1.02 -$9.68
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$44.6 -$42.35 -$45.64 -$111.27
Operating activities
Depreciation $0.64 $1.49 $1.64 $1.69
Business acquisitions & disposals
Stock-based compensation $3.47 $5.72 $9.48 $12.46
Total cash flows from operations -$36.1 -$37.54 -$48.18 -$99.69
Investing activities
Capital expenditures -$0.01 -$0.03 -$0.48
Investments $35.64 $30.08 -$73.39
Total cash flows from investing $35.64 $30.07 -$73.42 -$0.48
Financing activities
Dividends paid
Sale and purchase of stock $0.24 $62.59 $142.2
Net borrowings -$2.87 -$0.53 $0.06 $18.71
Total cash flows from financing -$2.82 -$0.53 $60.82 $154.87
Effect of exchange rate
Change in cash and equivalents -$3.28 -$8 -$60.78 $54.7
Fundamentals
Market cap $157.35M
Enterprise value $163.84M
Shares outstanding 4.42M
Revenue $0.00
EBITDA -$41.04M
EBIT -$41.68M
Net Income -$44.60M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -3.53
EV/Sales N/A
EV/EBITDA -3.99
EV/EBIT -3.93
P/S ratio N/A
P/B ratio -22.79
Book/Share -1.56
Cash/Share 3.25
EPS -$10.08
ROA -111.56%
ROE -920.33%
Debt/Equity -5.09
Net debt/EBITDA -0.51
Current ratio 0.74
Quick ratio 0.74